TY - JOUR

T1 - Managing Access to Advanced Therapy Medicinal Products: Challenges for NHS Wales

AU - Champion, A.R.

AU - Lewis, S.

AU - Davies, S.

AU - Hughes, Dyfrig

PY - 2021/6

Y1 - 2021/6

N2 - Advanced Therapy Medicinal Products (ATMPs) which include gene and somatic-cell therapies and tissue-engineered medicines, have the potential to transform current care pathways by offering durable and potentially curative outcomes. However, they are exceptionally expensive, with prices exceeding £1m per patient in some cases. With an expectation that a large number of ATMPs will soon gain marketing authorisation (global market is estimated to reach £9bn to £14bn by 2025), healthcare payers and providers face a number of challenges to facilitate patient access to this new category of medicines.This viewpoint reflects on the experience of introducing ATMPs into the National Health Service in Wales where £1 in every £200 spent on medicines in Wales (2019/20) is expected to be on ATMPs for just 20 patients. Evidence to date makes it apparent that decisions regarding clinical and cost-effectiveness, and the scale of the budget impact of implementing ATMPs creates both financial and service risks. Consequently, there are significant policy implications. A critical examination is made of the approaches taken for the health technology assessment and appraisal of ATMPs, the methods of payment and service impacts of these medicines, and the approach taken to horizon scanning and subsequent modelling of the financial impact over the next 10 years.

AB - Advanced Therapy Medicinal Products (ATMPs) which include gene and somatic-cell therapies and tissue-engineered medicines, have the potential to transform current care pathways by offering durable and potentially curative outcomes. However, they are exceptionally expensive, with prices exceeding £1m per patient in some cases. With an expectation that a large number of ATMPs will soon gain marketing authorisation (global market is estimated to reach £9bn to £14bn by 2025), healthcare payers and providers face a number of challenges to facilitate patient access to this new category of medicines.This viewpoint reflects on the experience of introducing ATMPs into the National Health Service in Wales where £1 in every £200 spent on medicines in Wales (2019/20) is expected to be on ATMPs for just 20 patients. Evidence to date makes it apparent that decisions regarding clinical and cost-effectiveness, and the scale of the budget impact of implementing ATMPs creates both financial and service risks. Consequently, there are significant policy implications. A critical examination is made of the approaches taken for the health technology assessment and appraisal of ATMPs, the methods of payment and service impacts of these medicines, and the approach taken to horizon scanning and subsequent modelling of the financial impact over the next 10 years.

KW - advanced therapies

KW - cell therapy

KW - cost-effectiveness

KW - gene therapy

KW - regenerative medicine

U2 - https://doi.org/10.1111/bcp.14286

DO - https://doi.org/10.1111/bcp.14286

M3 - Article

VL - 87

SP - 2444

EP - 2449

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

IS - 6

ER -